The proportion of patients with multiple sclerosis (MS) at high risk of COVID-19 mortality is below 1% in a population-based MS cohort. Most of these patients, including most of the patients in the high-risk group, did not receive any disease-modifying treatments (DMTs).
Why this matters
Patients with MS over 60 years old have been shown to have an increased risk of COVID-19 mortality. Treatment of MS via immunomodulatory therapies may alter the components of the immune system and are associated with a greater infectious risk, such as infection with viral pathogens. Therefore, it is necessary to understand the risk of COVID-19 mortality in an MS population in relation to the use of these therapies.